

# Lionel AdÃ¡s

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6712163/publications.pdf>

Version: 2024-02-01

103  
papers

5,039  
citations

147801

31  
h-index

102487

66  
g-index

106  
all docs

106  
docs citations

106  
times ranked

4643  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i> , 2013, 122, 2943-2964.	1.4	567
2	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. <i>Leukemia</i> , 2011, 25, 1147-1152.	7.2	430
3	Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure. <i>Journal of Clinical Oncology</i> , 2011, 29, 3322-3327.	1.6	421
4	Myelodysplastic syndromes. <i>Lancet</i> , The, 2014, 383, 2239-2252.	13.7	352
5	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2662-2670.	1.6	265
6	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
7	Long-term outcome after bone marrow transplantation for severe aplastic anemia. <i>Blood</i> , 2004, 103, 2490-2497.	1.4	192
8	Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients*. <i>British Journal of Dermatology</i> , 2022, 186, 564-574.	1.5	174
9	Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. <i>Rheumatology</i> , 2016, 55, 291-300.	1.9	170
10	Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). <i>Journal of Clinical Oncology</i> , 2021, 39, 1575-1583.	1.6	169
11	Germline DDX41 mutations define a significant entity within adult MDS/AML patients. <i>Blood</i> , 2019, 134, 1441-1444.	1.4	153
12	Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. <i>Leukemia Research</i> , 2014, 38, 751-755.	0.8	141
13	Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. <i>Blood</i> , 2015, 125, 3447-3454.	1.4	104
14	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. <i>Leukemia</i> , 2021, 35, 3542-3550.	7.2	97
15	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. <i>EBioMedicine</i> , 2018, 31, 174-181.	6.1	72
16	UBA1 Variations in Neutrophilic Dermatitis Skin Lesions of Patients With VEXAS Syndrome. <i>JAMA Dermatology</i> , 2021, 157, 1349.	4.1	71
17	Azacitidine for the treatment of relapsed and refractory AML in older patients. <i>Leukemia Research</i> , 2015, 39, 124-130.	0.8	63
18	Autoimmune manifestations associated with myelodysplastic syndromes. <i>Annals of Hematology</i> , 2018, 97, 2015-2023.	1.8	63

#	ARTICLE	IF	CITATIONS
19	Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. <i>Haematologica</i> , 2018, 103, 212-220.	3.5	62
20	How we manage adults with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2020, 189, 1016-1027.	2.5	60
21	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. <i>Blood Advances</i> , 2021, 5, 176-184.	5.2	56
22	A variant erythroferrone disrupts iron homeostasis in <i>SF3B1</i> -mutated myelodysplastic syndrome. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	55
23	The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. <i>Blood</i> , 2012, 120, 5084-5085.	1.4	50
24	Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. <i>Leukemia Research</i> , 2016, 47, 136-141.	0.8	49
25	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. <i>Blood Advances</i> , 2020, 4, 1942-1949.	5.2	49
26	Prognostic impact of <i>DDX41</i> germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. <i>Blood</i> , 2022, 140, 756-768.	1.4	48
27	Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. <i>Leukemia Research</i> , 2015, 39, 501-504.	0.8	46
28	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases. <i>Leukemia Research</i> , 2011, 35, 863-867.	0.8	44
29	Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. <i>Blood Advances</i> , 2022, 6, 5132-5145.	5.2	43
30	Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. <i>Blood</i> , 2021, 138, 507-519.	1.4	40
31	A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. <i>Haematologica</i> , 2019, 104, 1565-1571.	3.5	39
32	Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. <i>Cancer Discovery</i> , 2021, 11, 3198-3213.	9.4	38
33	Prognostic significance of concurrent gene mutations in intensively treated patients with <i>IDH</i> -mutated AML, an ALFA study. <i>Blood</i> , 2021, 137, 2827-2837.	1.4	36
34	Preclinical modeling of myelodysplastic syndromes. <i>Leukemia</i> , 2017, 31, 2702-2708.	7.2	34
35	Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. <i>Autoimmunity Reviews</i> , 2017, 16, 903-910.	5.8	32
36	Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. <i>Leukemia</i> , 2021, 35, 2720-2724.	7.2	29

#	ARTICLE	IF	CITATIONS
37	Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease. <i>Leukemia</i> , 2021, 35, 2731-2733.	7.2	27
38	Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1585-1595.	7.2	24
39	Next-Generation Sequencing in Myeloid Neoplasm-Associated Sweet's Syndrome Demonstrates Clonal Relation between Malignant Cells and Skin-Infiltrating Neutrophils. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1873-1876.e5.	0.7	23
40	<i>t(8;21)(p11;q22)</i> mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents. <i>Haematologica</i> , 2018, 103, e455-e457.	3.5	22
41	Gastrointestinal Behçet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1782-1788.	1.3	22
42	Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 879-884.	3.4	21
43	Inflammatory disorders associated with trisomy 8 in myelodysplastic syndromes: French retrospective case-control study. <i>European Journal of Haematology</i> , 2019, 102, 63-69.	2.2	20
44	Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies. <i>British Journal of Haematology</i> , 2018, 182, 843-850.	2.5	18
45	Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Haematologica</i> , 2021, 106, 1414-1422.	3.5	17
46	Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2014, 38, 29-33.	0.8	16
47	Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. <i>Leukemia</i> , 2016, 30, 1416-1418.	7.2	16
48	Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. <i>Cancer</i> , 2015, 121, 2393-2399.	4.1	15
49	Clinical, pathological, and molecular features of myelodysplasia cutis. <i>Blood</i> , 2022, 139, 1251-1253.	1.4	15
50	Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. <i>Leukemia Research</i> , 2017, 63, 72-77.	0.8	14
51	Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review. <i>Autoimmunity Reviews</i> , 2020, 19, 102446.	5.8	13
52	Impact of Cytogenetics and Cytogenetic Response On Outcome in MDS Treated with Azacitidine (AZA).. <i>Blood</i> , 2012, 120, 2807-2807.	1.4	13
53	A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. <i>British Journal of Haematology</i> , 2022, 198, 535-544.	2.5	12
54	Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954). <i>Blood</i> , 2021, 138, 242-242.	1.4	10

#	ARTICLE	IF	CITATIONS
55	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1160-1170.	2.0	9
56	Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. <i>Leukemia</i> , 2021, 35, 225-228.	7.2	9
57	Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325). <i>Blood</i> , 2011, 118, 609-609.	1.4	8
58	Autoantibodies in myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2594-2596.	1.3	7
59	Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. <i>Blood Advances</i> , 2019, 3, 3579-3589.	5.2	7
60	Azacitidine Treatment for Lenalidomide (LEN)-Resistant Myelodysplastic Syndrome (MDS) with Del 5q. <i>Blood</i> , 2012, 120, 3833-3833.	1.4	7
61	Outcome Of Patients With IPSS Intermediate (int) Or High Risk Myelodysplastic Syndrome (MDS) According To Donor Availability: A Multicenter Prospective Non Interventional Study For The SFGM-TC and GFM. <i>Blood</i> , 2013, 122, 301-301.	1.4	7
62	Prognostic Factors of Severe Infections, and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA). A Single Center Study On 144 Patients. <i>Blood</i> , 2012, 120, 3812-3812.	1.4	7
63	Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients. <i>Blood</i> , 2013, 122, 389-389.	1.4	6
64	Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series. <i>Frontiers in Immunology</i> , 2021, 12, 715053.	4.8	6
65	A multiparametric niche-like drug screening platform in acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	6
66	Guadecitabine in myelodysplastic syndromes: promising but there is still progress to be made. <i>Lancet Haematology</i> , 2019, 6, e290-e291.	4.6	5
67	The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs. <i>Cancer Journal (Sudbury, Mass )</i> , 2022, 28, 29-36.	2.0	5
68	Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. <i>Leukemia Research</i> , 2018, 71, 67-74.	0.8	4
69	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. <i>Leukemia</i> , 2018, 32, 2066-2069.	7.2	4
70	Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 12-13.	1.4	4
71	Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac088.	0.9	4
72	Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine. <i>Blood</i> , 2012, 120, 1706-1706.	1.4	3

#	ARTICLE	IF	CITATIONS
73	Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. <i>Blood</i> , 2012, 120, 422-422.	1.4	3
74	Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1365-1372.	2.4	3
75	Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 1214-1219.	0.8	2
76	Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes. <i>Hemato</i> , 2021, 2, 329-346.	0.6	2
77	Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q. <i>Blood</i> , 2011, 118, 2786-2786.	1.4	2
78	Potential of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib. <i>Blood</i> , 2011, 118, 2790-2790.	1.4	2
79	Arsenic Trioxide-Based Therapy Of Relapsed Acute Promyelocytic Leukemia: Updated Results Of The European Registry Of Relapsed APL (PROMYSE). <i>Blood</i> , 2013, 122, 1406-1406.	1.4	2
80	A Phase II Study Of The Efficacy and Safety Of An Intensified Schedule Of Azacitidine (AZA) In Intermediate-2 and High Risk MDS Patients. <i>Blood</i> , 2013, 122, 1513-1513.	1.4	2
81	Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2013, 122, 620-620.	1.4	2
82	A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q "A Study By The Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2013, 122, 2750-2750.	1.4	2
83	Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf Tj ETQq1 1 0.784314 rgBT /Overlo		
84	Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML). <i>Blood</i> , 2012, 120, 3811-3811.	1.4	1
85	Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts). <i>Blood</i> , 2012, 120, 890-890.	1.4	1
86	Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS " Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies. <i>Blood</i> , 2012, 120, 1720-1720.	1.4	1
87	Impact Of Myelofibrosis (MF) In MDS Treated With Azacitidine (AZA). A Single Center Study. <i>Blood</i> , 2013, 122, 1539-1539.	1.4	1
88	The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, DÄ¼sseldorf Registry and Fism. <i>Blood</i> , 2013, 122, 2761-2761.	1.4	1
89	Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID). <i>Blood</i> , 2021, 138, 1496-1496.	1.4	1
90	Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine. <i>Annals of Hematology</i> , 2018, 97, 541-542.	1.8	0

#	ARTICLE	IF	CITATIONS
91	Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital. <i>Blood Cancer Journal</i> , 2021, 11, 129.	6.2	0
92	Allogeneic Hematopoietic Peripheral Blood Stem-Cell Transplantation From HLA-Identical Siblings Versus Allelic-Matched Unrelated Donors (10/10 high resolution) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced Intensity Conditioning. <i>Blood</i> , 2011, 118, 4132-4132.	1.4	0
93	Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacitidine (AZA). <i>Blood</i> , 2011, 118, 5028-5028.	1.4	0
94	Equivalent Outcome Between Reduced Intensity Versus Conventional Myeloablative Conditioning Hematopoietic Stem Cell Transplantation for Patients Older Than 35 Years with Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 3103-3103.	1.4	0
95	Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q. <i>Blood</i> , 2012, 120, 2809-2809.	1.4	0
96	A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure. <i>Blood</i> , 2012, 120, 1719-1719.	1.4	0
97	Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents. <i>Blood</i> , 2012, 120, 2035-2035.	1.4	0
98	Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML). <i>Blood</i> , 2012, 120, 309-309.	1.4	0
99	Effector CD4 <sup>+</sup> CD45RA <sup>hi</sup> CD25 <sup>bright</sup> Foxp3 <sup>bright</sup> Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status. <i>Blood</i> , 2012, 120, 2808-2808.	1.4	0
100	NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2012, 120, 3835-3835.	1.4	0
101	Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL – Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. <i>Blood</i> , 2013, 122, 495-495.	1.4	0
102	Prognostic Factors of Infections and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA): A Prospective Study. <i>Blood</i> , 2014, 124, 1917-1917.	1.4	0
103	BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 3261-3261.	1.4	0